Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

Abstract Background Programmed Death Ligand 1 (PD-L1) is a co-stimulatory and immune checkpoint protein. PD-L1 expression in non-small cell lung cancers (NSCLC) is a hallmark of adaptive resistance and its expression is often used to predict the outcome of Programmed Death 1 (PD-1) and PD-L1 immunot...

Full description

Bibliographic Details
Main Authors: Kim A. Brogden, Deepak Parashar, Andrea R. Hallier, Terry Braun, Fang Qian, Naiyer A. Rizvi, Aaron D. Bossler, Mohammed M. Milhem, Timothy A. Chan, Taher Abbasi, Shireen Vali
Format: Article
Language:English
Published: BMC 2018-02-01
Series:BMC Cancer
Subjects:
Computational modeling
PD-1
PD-L1
NSCLC
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-018-4134-y

Internet

http://link.springer.com/article/10.1186/s12885-018-4134-y

Similar Items